Lilly To Increase Investment In Chongqing
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly officials recently visited Chongqing to seek market expansion. The firm has been forging a long-term collaboration with local medical institutions and colleges particularly in diabetes, where it will increase investment in areas such as public education, welfare services and academic exchange. It plans to add at least 800 employees in China and double the staff number in Chongqing to make it the top revenue generator in south-west China. Lilly is optimistic about Chongqing thanks to the latter's substantial strength in healthcare and talent. In addition, the city leads the push to implement urban-rural integrated medical insurance, which covers more patients, making it attractive to pharmaceutical companies. (Click here for more - Chinese Language)
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.